Phase 3 Readout
CRNX: Phase 3 Topline: Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthel
June 1, 2026 · pembrolizumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2026
- Company
- Crinetics Pharmaceuticals, Inc. (CRNX)
- Drug
- pembrolizumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthel
- Drug
- pembrolizumab
- Indication
- Locally Advanced Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Other upcoming events for CRNX
Phase 3 ReadoutPhase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu
Phase 3 ReadoutPhase 3 Topline: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Plac
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative